Strasbourg biotech appoints ceo

7-May-2010

Mark Bloomfield aims to accelerate sales growth at Polyplus-transfection

Polyplus-transfection, a Strasbourg-based biotechnology firm developing solutions for scientists working in molecular and cell biology, has appointed Mark Bloomfield as chief executive.

Bloomfield replaces Frédéric Perraud who continues with Polyplus as chief operating officer and deputy ceo.

Polyplus is planning to accelerate revenue growth by launching reagents and solutions for cell transfection applications, by the commercialisation of ZNA technology through licensing agreements with Sigma-Aldrich and Metabion, as well as geographical sales channel expansion with partners in the US and major European and Asian markets.



Bloomfield has a background in chemistry and joins Polyplus-transfection after more than 15 years in sales and management positions with global companies in the biotechnology tools and analytical instruments markets.

‘I am very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth,’ said Bloomfield.

Companies